dtri-031
Nucleic acidexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 20, 2021 (NCT05005520)
Timeline
Indications
Mechanism of action
- von Willebrand factorINHIBITOR
VWF inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07202663 | Phase 1 | Nov 5, 2025 | Basking Biosciences, Inc., Scientia Clinical Research Limited Sydney |
| NCT06226805 | Phase 2 | Jul 31, 2024 | Basking Biosciences, Inc., Ohio State University, University of Calgary |
| NCT05005520 | Phase 1 | Oct 20, 2021 | Basking Biosciences, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Basking Biosciences, Inc. | For profit | 3 | 3 | 2 | 2021 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Scientia Clinical Research Limited Sydney | For profit | 1 | 0 | 1 | 2025 |
| University of Calgary | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1